These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25359549)

  • 1. Research use exemptions to patent infringement for drug discovery and development in the United States.
    Russo AA; Johnson J
    Cold Spring Harb Perspect Med; 2014 Oct; 5(2):a020933. PubMed ID: 25359549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug discovery and the impact of the safe harbor provision of the Hatch- Waxman Act.
    Goodson SH
    Curr Top Med Chem; 2010; 10(18):1960-70. PubMed ID: 20615186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Judicial developments in the US Hatch-Waxman infringement safe harbor.
    Swirnoff AH; Becker DM
    Expert Opin Ther Pat; 2010 Apr; 20(4):451-8. PubMed ID: 20302449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Australia experiments with 'experimental use' exemption.
    McBratney A; Nielsen K; McMillan F
    Nat Biotechnol; 2004 Aug; 22(8):1023-5. PubMed ID: 15286651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent tactics in molecular diversity: things that get around, come around (or: there are always exceptions to the rule).
    Bozicevic K
    Mol Divers; 1997-1998; 3(4):235-46. PubMed ID: 9850520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research exemption/experimental use in the European Union: patents do not block the progress of science.
    Jaenichen HR; Pitz J
    Cold Spring Harb Perspect Med; 2014 Nov; 5(2):a020941. PubMed ID: 25377145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will changes to patent infringements attract drug research in the UK?
    Snodin M
    Expert Opin Ther Pat; 2015; 25(9):949-51. PubMed ID: 25813963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US courts narrow patent exemptions.
    Fox JL
    Nat Biotechnol; 2003 Aug; 21(8):834. PubMed ID: 12894182
    [No Abstract]   [Full Text] [Related]  

  • 10. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
    Dougherty MP
    Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patentee bears burden of proof when licence agreements are questioned.
    Harrison C
    Nat Rev Drug Discov; 2014 Mar; 13(3):168. PubMed ID: 24577391
    [No Abstract]   [Full Text] [Related]  

  • 12. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amendment to UK Patent Act provides further exception to patent infringement.
    Sklan A
    Pharm Pat Anal; 2014 Jul; 3(4):349. PubMed ID: 25291308
    [No Abstract]   [Full Text] [Related]  

  • 15. PMA primacy: synthesizing the 35 U.S.C. Section 156 patent term extension, 35 U.S.C. Section 271(e)(1) patent infringement exemption as currently applied to medical devices, and medical device preemption jurisprudence to yield a cohesive solution regarding scope of coverage.
    Flaherty JM
    Food Drug Law J; 2001; 56(3):339-49. PubMed ID: 11944643
    [No Abstract]   [Full Text] [Related]  

  • 16. Navigating the Hatch-Waxman Act's safe harbor.
    Jones PB
    Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
    [No Abstract]   [Full Text] [Related]  

  • 17. Licensing research tool patents.
    Flattmann GJ; Kaplan JM
    Nat Biotechnol; 2002 Sep; 20(9):945-7. PubMed ID: 12205511
    [No Abstract]   [Full Text] [Related]  

  • 18. Navigating the Safe Harbor: guidance from the courts on qualifying for the 35 U.S.C. 271(e)(1) exemption from patent infringement of health care related inventions.
    Chickos SJ
    J Contemp Health Law Policy; 2007; 24(1):43-68. PubMed ID: 18507356
    [No Abstract]   [Full Text] [Related]  

  • 19. Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade.
    Grabowski H; Vernon J
    Pharmacoeconomics; 1996; 10 Suppl 2():110-23. PubMed ID: 10163428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of Food and Drug Administration 510(k) notifications in patent litigation.
    Tolomeo DE
    Food Drug Law J; 2004; 59(4):465-77. PubMed ID: 15875346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.